<div id="readability-page-1"><h3>Claim 50% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>An update from SinoMab Bioscience Ltd. ( (HK:3681) ) is now available. SinoMab BioScience has received approval from China’s National Medical Products Administration for an investigational new drug application to test SM17 in inflammatory bowel disease, expanding the molecule’s scope beyond atopic dermatitis. The company has completed a Phase I subcutaneous bridging study in healthy volunteers and plans to use the data to support further clinical development, including Phase II trials. SM17 is a first‑in‑class humanized monoclonal antibody targeting the IL‑25 receptor to modulate Type 2 inflammatory responses, positioning it as a differentiated option for ulcerative colitis and potentially Crohn’s disease. SinoMab views the new IBD indication, alongside ongoing formulation work and an upcoming Phase II trial in atopic dermatitis, as a major clinical and commercial opportunity in a market where many patients do not respond durably to existing biologics. The most recent analyst rating on (HK:3681) stock is a Sell with a HK$1.50 price target. To see the full list of analyst forecasts on SinoMab Bioscience Ltd. stock, see the HK:3681 Stock Forecast page. More about SinoMab Bioscience Ltd. SinoMab BioScience Limited is a Hong Kong‑incorporated biopharmaceutical company focused on developing first‑in‑class monoclonal antibody therapies. The group’s pipeline targets immune‑mediated and inflammatory diseases, with a particular emphasis on Type 2 inflammation and conditions such as atopic dermatitis and inflammatory bowel disease in major global markets. Average Trading Volume: 5,291,021 Technical Sentiment Signal: Buy Current Market Cap: HK$2.68B </div>

159859

512290

03681

SinoMab Bioscience Ltd. has received approval from China's National Medical Products Administration for an investigational new drug application to test SM17 in inflammatory bowel disease, expanding its use beyond atopic dermatitis. The company completed a Phase I study and plans to advance to Phase II trials. SM17 is a humanized monoclonal antibody targeting the IL-25 receptor, offering a new option for ulcerative colitis and Crohn's disease. Analysts currently rate the stock as a Sell with a price target of HK$1.50.

SinoMab Wins China IND Nod to Expand SM17 Into Inflammatory Bowel Disease